Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oregovomab + Chemo in Advanced Ovarian Cancer
NCT01616303Phase 2Completed
- Sponsor
- Quest PharmaTech Inc.
- Start
- Jun 2012
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of oregovomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Quest PharmaTech Inc.. Started Jun 2012; status: completed.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01616303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01616303.